Catamenial epilepsy occurrence and patterns in a mixed population of women with epilepsy.
catamenial epilepsy
electronic seizure diary
women's health
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
12
07
2023
received:
07
02
2023
accepted:
12
07
2023
medline:
20
9
2023
pubmed:
15
7
2023
entrez:
15
7
2023
Statut:
ppublish
Résumé
We evaluated the occurrence and distribution of patterns of catamenial epilepsy in a heterogenous cohort of women with epilepsy on no hormonal therapies, enrolled in a prospective, observational study. The primary aim of the study was pregnancy rate in women with epilepsy with no prior reproductive problems. In this analysis, we included women who recorded one or more menstrual cycles with one or more seizures. We measured progesterone concentrations for one to three cycles. We defined catamenial patterns as twofold or greater average daily seizure frequency around menstruation (C1), ovulation (C2), and for anovulatory cycles, from midcycle through menstruation (C3). Twenty-three of the 89 enrolled women with epilepsy were eligible for this analysis; 12 of 23 met criteria for catamenial epilepsy; five of 23 demonstrated only a C1 pattern, two of 23 only a C2 pattern, five of 23 a combined C1/C2 pattern, and the one woman with anovulatory cycles did not demonstrate a C3 pattern. There were no differences in likelihood of demonstrating a catamenial pattern between those who reported a prior catamenial pattern and those who did not (p = .855). This analysis demonstrates the utility of app-based tracking to determine a catamenial pattern. Larger prospective studies could confirm these findings and inform potential therapeutic trial designs for catamenial epilepsy.
Substances chimiques
Progesterone
4G7DS2Q64Y
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e194-e199Informations de copyright
© 2023 International League Against Epilepsy.
Références
Harden CL, Pennell PB. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12(1):72-83.
Reddy DS. The neuroendocrine basis of sex differences in epilepsy. Pharmacol Biochem Behav. 2017;152:97-104.
Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38(10):1082-1088.
Herzog AG, Fowler KM, Smithson SD, Kalayjian LA, Heck CN, Sperling MR, et al. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology. 2012;78(24):1959-1966.
Pennell PB, French JA, Harden CL, Davis A, Bagiella E, Andreopoulos E, et al. Fertility and birth outcomes in women with epilepsy seeking pregnancy. JAMA Neurol. 2018;75:962-969.
Ernst LL, Harden CL, Pennell PB, Llewellyn N, Lau C, Barnard S, et al. Medication adherence in women with epilepsy who are planning pregnancy. Epilepsia. 2016;57(12):2039-2044.
Cagnetti C, Lattanzi S, Foschi N, Provinciali L, Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;83(4):339-344.
Herzog AG. Catamenial epilepsy: update on prevalence, pathophysiology and treatment from the findings of the NIH progesterone treatment trial. Seizure. 2015;28:18-25.
Laidlaw J. Catamenial epilepsy. Lancet. 1956;271(6955):1235-1237. PMID: 13386215. https://doi.org/10.1016/s0140-6736(56)90003-4
Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia. 1993;34(6):1007-1016.